A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)

Size: px
Start display at page:

Download "A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP)"

Transcription

1 A Daily Pill to Prevent HIV: Oral Pre-exposure Prophylaxis (PrEP) Delivette Castor, PhD USAID Jason Reed, MD, MPH Jhpiego Timothy Mah, DSc USAID Global Health Mini-University September 14, 2017

2 Presentation Overview Oral PrEP Basics What is it? How does it prevent HIV? Who might benefit from Oral PrEP? PrEP Policy and Guidance PrEP introduction and scaleup in SSA What s next? 2

3 What is oral PrEP? A pill taken daily by HIV-negative individuals to reduce their risk of HIV Contains anti-hiv medicine(s) that have been widely used to treat HIV infection Comprised of Tenofovir (TDF) alone or in combination with Emtricitabine (FTC) or Lamivudine (3TC) Brand name (non-generic name) of TDF/FTC combination is Truvada

4 How does oral PrEP prevent HIV? When HIV-negative people take oral PrEP, concentration of anti-hiv medicine(s) gradually builds in their bodies (if they take as prescribed) Should they subsequently be exposed to HIV, the medicine prevents the virus from infecting their body s cells This is similar to the way in which oral contraceptives work to prevent pregnancy and malaria prophylaxis works to prevent malaria

5 How does oral PrEP prevent HIV? HIV Transmitted

6 How does oral PrEP prevent HIV? HIV Not Transmitted

7 What is the evidence that oral PrEP works? Scientific data from a large number of clinical trials and demonstration projects have proven that PrEP is effective at preventing HIV infection On-demand Truvada MSM- France (IPERGA Y) Daily Truvada MSM- UK (PROUD ) Daily Truvada Discordant Couples- Uganda, Kenya (Partners PrEP) Daily Tenofov ir Discordant Couples- Uganda, Kenya (Partners PrEP) Daily Truvada Heterosexu al M & F- Botswana (TDF2) Daily Truvada MSM- America s, Thailand, South Africa (iprex) Daily Truvada Women- Kenya, South Africa, Tanzania (FEMPr EP) Daily Truvada Women- South Africa, Uganda, Zimbabwe (MTN003/ VOICE) Daily Viread Women- South Africa, Uganda, Zimbabwe (MTN003/ VOICE)

8 Consistent protective effect across 5 studies 4 of the 5 studies show >80% protection Evidence in men is compelling (MSM > discordant couples > general heterosexual men) 9/22/2017 8

9 Oral PrEP inconsistent effectiveness across 4 studies Topical PrEP inconsistent effectiveness across 3 studies Effectiveness consistent in those with detectable drug levels 9/22/2017 FOOTER GOES HERE 9

10 PrEP is Over 90% Effective Results indicated that oral PrEP when taken as prescribed over 90% effective at protecting HIV-negative people against HIV In the FTC TDF group, among subjects with a detectable study-drug level, as compared with those without a detectable level, the odds of HIV infection were lower by a factor of 12.9 (95% CI, 1.7 to 99.3; P<0.001), corresponding to a relative reduction in HIV risk of 92% (95% CI, 40 to 99; P<0.001). After adjustment for reported unprotected receptive anal intercourse, the relative risk reduction was 95% (95% CI, 70 to 99; P<0.001). Citation: Grant, Robert M., et al. "Preexposure chemoprophylaxis for HIV prevention in men who have sex with men." New England Journal of Medicine (2010):

11 PrEP Guidance 11

12 WHO Guidance & Support In response to the evidence, WHO issued series of guidance documents, culminating in their 2016 recommendation: oral PrEP be made available to anyone at substantial risk of becoming infected with HIV Added Oral PrEP to the WHO Essential Medicines List in 2017 Released the WHO Oral PrEP Implementation Tool in July

13 PrEP Trajectory in PEPFAR PEPFAR SAB recommends PrEP implementation Pre USAID supported Partner s PrEP OLE, Partner s Demo, FEM-PrEP & several demonstration studies COP Guidance encouraged stakeholder coordination and PrEP readiness activities. - Drug procured w/ non-pepfar funds - DREAMS sites can initiate PrEP - PrEP interagency TF formed Guidance allows for procurement of PrEP ARVs when Test & START policy initiated VL testing in place multi-month scripting for stable ART clients COP guidance Forthcoming 13

14 PEPFAR FY18 PrEP Targets ,000 1,300 1,550 1,680 1,700 1,700 2,769 4,496 11,757 12,815 16,150 23,993 Oct Sept 2018 Total = 82, 096 UNAIDS 2020: 3 Million 14

15 Country Progress on Oral PrEP South Africa PrEP rollout at Sex Worker sites (Mar 2016) Kenya National Oral PrEP Rollout (May 2017) Namibia PrEP Guidelines (WAD 2016) 15

16 PrEP Introduction and Scale-up 16

17 Who might benefit from PrEP? High and medium incidence comprise 95% of HIV infections 17

18 Who might benefit from PrEP? 18

19 Cost and Impact of Potential Roll Out Scenarios 19

20 Framework for Scaling up PrEP OPTIONS project: 20

21 Countries with Demonstration Projects 21

22 CAPRISA 084: PrEP Demonstration Project Objectives: To assess the feasibility, acceptability, uptake and patterns of use of daily, oral tenofovir diproxyl fumarate + emtricitabine provided as part of SRH services to young women (and men) at risk of acquiring HIV in urban and rural KwaZulu-Natal Determine contraceptive use patterns; STIs and pregnancy rates among female PrEP clients Develop a critical mass of trained health care workers skilled to provide PrEP and integrate HIV services into SRH services Characterize PrEP seekers and succesful users Monitor safety of PrEP use in routine services Describe patterns of PrEP use including adherence Determine factors that influence use patterns and adherence What client and provider support is needed for PrEP use? 5

23 CAPRISA 084: Study Sites & Population Enroll clients on oral PrEP Total RURAL Vulindlela n=1200 ANC + FP Clinics + School SRH services URBAN ethekwini n=500 STI clinic + FP clinic + Tertiary institutions PERI-URBAN Umlazi n=300 Pregnant + postpartum Men Age (years) (Range) # enrolled & offered PrEP # (%) initiating PrEP 23.3 (18-30) (61%) # Still on PrEP after 6 months 166 (64%) # Still on PrEP after 12 months As of July (52%) 6

24 CAPRISA 084: Reasons for non-use of PrEP Reasons for not initiating PrEP Not interested / willing / ready to take PrEP HIV test positive, abnormal ALT/AST, medical condition No self-perceived HIV risk Concerned about objection from partner Reasons for stopping PrEP Bad allergic reaction/ rash and swelling of the upper body, Not willing to take ARV medication, Unavailable because of work, No money for transport to get to the clinic, or No longer interested due to lower HIV risk perception

25 Bridge to Scale: Program Overview

26 Overall Project Goal To demonstrate and document an effective model for how oral Pre-exposure Prophylaxis (PrEP) can be scaled up as an HIV-prevention intervention in low-resource settings

27 Priority Population for PrEP Female sex workers (FSWs) Men who have sex with other men (MSM), including male sex workers Adolescent girls and young women (AGYW)

28 Geographic Locations

29 Kenya s PrEP Scale-up Milestones

30 Key Bridge to Scale Milestones

31 Sub Goal 1: Demonstrate Effectiveness of Population Level PrEP Interventions Supply Integrate PrEP into existing combination prevention services Demand Human Centered Design Behavioral Economics

32 Bridge to Scale Service Delivery Points Bridge to Scale Service Delivery Points PrEP is delivered using facility-based and community-based models Drop in Centers - 18 Public Health Facilities - 26 Private Health Facilities - 7 Outreach 32

33 Demand Creation Framework

34 National PrEP Campaign Identity

35 Sub Goal 2: Develop and document an acceptable, affordable, and replicable approach to launch and scale-up the use of oral PrEP Learning laboratory Costing, impact, and affordability (Modeled) Replicability Implementation toolkit

36 Sub Goal 3: Country level & International advocacy Implementation guidelines Domestic and international financing Systems to enable scale up Ensure political, donor, and community support for the scale-up of oral PrEP

37 Media Engagement

38

39 Planned Activities Service Delivery Capacity building of health providers Provision of job aids for providers Commodity quantification based on actual consumption Strengthen supply chain and commodity reporting

40 Demand Creation Less Mass Media and increased Interpersonal Communication

41 Crisis Communications Risk mapping Political, cultural, religious resistance Anti-PrEP activism Risk compensation leading to infection Crisis committee formed Interim crisis strategy in place

42 What is next? 42

43 Different Strokes for Different Folks Method Contraception HIV Prevention Behaviour Barrier Methods Gels not registered Rings with regulatory body Oral pill Injectables? 1 ARV, 1 bnab, 2 vax in/near phase 3; others in pre. Implants? multiple in preclinical Surgical procedures Treatment Prevention Paradigm 2017 and Beyond Source: AVAC.org

44 USAID Microbicide Product Introduction Initiative (MPii) Product R&D Antibodies Long Acting Injectables Films Rings Pre-Clinical T1 - Translation to Human (Move a molecule into product ) T2 - Translation to Patients/Practice (Generate the real world evidence) T3 - Translation to Program (Introduce in existing health systems and scale-up) Minimize delays in introducing HIV/AIDS prevention Better prepare national health systems to deliver new HIV prevention products to Women 9/22/

45

46 THANK YOU! Delivette Castor Jason Reed Timothy Mah 46

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF

ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF ETHICS IN HIV PREVENTION RESEARCH IN THE NEW ERA OF PrEP MTN Regional Meeting Cape Town 20 September 2017 Dhevium Govender South African Medical Research Council HIV Prevention Research Unit Quality/Regulatory

More information

Understanding the Results of VOICE

Understanding the Results of VOICE CONTACT: Lisa Rossi +1-412- 916-3315 (mobile) or +27-(0)73-323-0087 (through 7 March) rossil@upmc.edu About VOICE Understanding the Results of VOICE VOICE Vaginal and Oral Interventions to Control the

More information

HIV Prevention Strategies HIV Pre-exposure prophylaxis

HIV Prevention Strategies HIV Pre-exposure prophylaxis HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those

More information

Implementation of PrEP in Kenya

Implementation of PrEP in Kenya Implementation of PrEP in Kenya National AIDs & STI Control Program Ministry of Health November 2017 HIV in Kenya Context Kenya has the world s fourth largest HIV burden, 1.5 million people living with

More information

Overview and Status of PrEP in Kenya

Overview and Status of PrEP in Kenya Overview and Status of PrEP in Kenya Elizabeth Irungu, MBChB, MPH Country Director, Partners Scale Up Project Kenya Stakeholders Meeting on REACH February 8, 2018 Outline National program brief PrEP projects

More information

Where are we going after effectiveness studies?

Where are we going after effectiveness studies? Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years

More information

ARVs for prevention in at-risk populations: Microbicides

ARVs for prevention in at-risk populations: Microbicides ARVs for prevention in at-risk populations: Microbicides Treatment as Prevention in Africa Meeting Botswana, April 30 May 3, 2014 Salim S Abdool Karim Director: CAPRISA Pro Vice-Chancellor (Research):

More information

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel

Inspiring HIV Prevention Innovations for Women. IPM Satellite Event Durban, 13 th June 2017 Annalene Nel Inspiring HIV Prevention Innovations for Women IPM Satellite Event Durban, 13 th June 2017 Annalene Nel HIV Infection: Where We Are Today 30+ years since the US CDC reported the first cases of AIDS 25.5

More information

Update on roll out of PrEP

Update on roll out of PrEP Update on roll out of PrEP Dr Rachel Baggaley, Michelle Rodolph, Dr Shona Dalal, Dr Ioannis Hodges-Mameletzis WHO HIV Department Geneva, Switzerland Regulatory pathways and clinical trial design for long-acting

More information

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention

Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention Pre-Exposure Prophylaxis (PrEP) A Biomedical Intervention Prevention with Negatives Antiretroviral Prevention New and Emerging Biomedical HIV Prevention Interventions Vaccines Vaginal microbicides Pre-exposure

More information

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE CONTACT: Lisa Rossi +1-412-641-8940 +1-412- 916-3315 (mobile) rossil@upmc.edu QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE 1. What is the Partners PrEP study? The Partners PrEP Study is a double-blind,

More information

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE

The HIV Prevention Pill: The State of PrEP Science and Implementation. James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE Overview 1. The Basics 2. A review of the science 3. An update

More information

Update on PrEP progress: WHO/UNAIDS challenges and actions

Update on PrEP progress: WHO/UNAIDS challenges and actions Update on PrEP progress: WHO/UNAIDS challenges and actions Kevin R. O'Reilly Prevention in the Health Sector, HIV/AIDS Department, WHO HQ Outline Review current status of PrEP Planning for PrEP Pre-exposure

More information

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.

Disclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000. Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD

More information

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare

HIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987

More information

HP+/Project SOAR Oral PrEP Modeling. Webinar Series: Five Ways to Accelerate Progress Toward the Goals January 16, 2018

HP+/Project SOAR Oral PrEP Modeling. Webinar Series: Five Ways to Accelerate Progress Toward the Goals January 16, 2018 HP+/Project SOAR Oral PrEP Modeling Webinar Series: Five Ways to Accelerate Progress Toward the 95-95-95 Goals January 16, 2018 Activity Overview 2 Activity Objective Provide impact, cost, and cost-effectiveness

More information

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D.

Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics

More information

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated

More information

Using anti-hiv drugs for prevention

Using anti-hiv drugs for prevention Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment

More information

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women

What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women What do you think about? Beyond Phase III: Seeking stakeholder perspectives on next steps with the dapivirine ring for HIV prevention in women 6 August 2014, Lilongwe Question #1 HIV testing and safety

More information

The Big Picture: The current and evolving HIV prevention landscape

The Big Picture: The current and evolving HIV prevention landscape The Big Picture: The current and evolving HIV prevention landscape Sharon Hillier, Ph.D. University of Pittsburgh Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine

More information

Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT

Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT 4 Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 4: READINESS ASSESSMENT About this toolkit WHAT IS THE PURPOSE AND CONTENTS OF THIS TOOLKIT? This toolkit was developed and used by the OPTIONS

More information

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples

More information

OPTIONS REVIEW AND DOCUMENTATION OF M&E INDICATORS FOR ORAL PrEP

OPTIONS REVIEW AND DOCUMENTATION OF M&E INDICATORS FOR ORAL PrEP OCTOBER 2016 OPTIONS REVIEW AND DOCUMENTATION OF M&E INDICATORS FOR ORAL PrEP Overview of this review Goals of this work Collect Information Summarize current M&E efforts for oral PrEP at the global, country

More information

The Big Picture: The current and evolving HIV prevention landscape

The Big Picture: The current and evolving HIV prevention landscape The Big Picture: The current and evolving HIV prevention landscape Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking stakeholder perspectives on next steps with the for HIV

More information

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure

More information

The Open Label Trial Past and Present

The Open Label Trial Past and Present The Open Label Trial Past and Present Patrick Ndase, MBChB, M.P.H University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention

More information

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City

Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000

More information

ART and Prevention: What do we know?

ART and Prevention: What do we know? ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:

More information

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society

WOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with

More information

The Open Label Trial Past and Present

The Open Label Trial Past and Present The Open Label Trial Past and Present Jared Baeten, M.D., Ph.D. University of Washington Beyond Phase III: Seeking civil society perspectives on next steps with the dapivirine ring for HIV prevention in

More information

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women:

Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Pre-Exposure Prophylaxis (PrEP) 1 Prevention of HIV in At-Risk Women: Coming of Age Aaron Kofman, BA, MD 14 Eli Y. Adashi, MD, MS, CPE, FACOG BRIGHT Series June 12, 2012 Women and the HIV Epidemic Global

More information

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time.

PrEP for Women. Together, we can change the course of the HIV epidemic one woman at a time. PrEP for Women Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is PrEP? PrEP stands for Pre- Exposure Prophylaxis: Prophylaxis: Taking

More information

PrEP efficacy the evidence

PrEP efficacy the evidence PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine

More information

Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa

Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa SUMMARY REPORT Progress in scaling up voluntary medical male circumcision for HIV prevention in East and Southern Africa January December 2012 Table of contents List of acronyms 2 Introduction 3 Summary

More information

Translating the Science to End New HIV Infections in Kenya

Translating the Science to End New HIV Infections in Kenya Translating the Science to End New HIV Infections in Kenya Perspectives, Practices and Lessons Nairobi, 28-30 May 2017 www.iasociety.org AIDS 2016 Post-Conference Workshop Setting the Stage Overview of

More information

Successful results of clinical trials

Successful results of clinical trials Successful results of clinical trials Four clinical trials for HIV prevention in past two years showed different degrees of efficacy > HPTN 052 showed 96% reduction in HIV transmission from HIV infected

More information

Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143

Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak. Pilkington et al. Glasgow HIV Poster 0143 Victoria Pilkington, Andrew Hill, Sophie Hughes, Nneka Nwokolo and Anton Pozniak 36.7 Million 1.8 Million 1 Million NEW INFECTIONS LIVING WITH HIV DEATHS https://www.avert.org/global-hiv-and-aids-statistics.

More information

On the Horizon for Consideration: Biomedical Advances in HIV Prevention

On the Horizon for Consideration: Biomedical Advances in HIV Prevention On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council

More information

Biomedical Prevention Update Thomas C. Quinn, M.D.

Biomedical Prevention Update Thomas C. Quinn, M.D. Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global

More information

Novel HIV Prevention Methods for Women

Novel HIV Prevention Methods for Women Novel HIV Prevention Methods for Women State of the art injectables, rings, and antibody-mediated prevention Nyaradzo M Mgodi (MBChB, MMed) Principal Investigator University of Zimbabwe- College of Health

More information

PrEP Dosing Strategies

PrEP Dosing Strategies PrEP Dosing Strategies Outline o Background PrEP absorption and tissue penetration o Oral versus topical o Lead in and lead out dosing Time to protection o Cycling on and off PrEP o Balancing toxicity

More information

The HIV Prevention Pill: The State of PrEP Science and Implementation

The HIV Prevention Pill: The State of PrEP Science and Implementation The HIV Prevention Pill: The State of PrEP Science and Implementation James Wilton Coordinator, Biomedical Science of HIV Prevention CATIE December 11 th, 2014 Overview 1. The Basics 2. A review of the

More information

Summary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa

Summary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa March 2017 Summary of Expected Insights on Oral PrEP for AGYW from Demo Projects in South Africa Wits RHI in partnership with FSG and AVAC Work in progress for discussion Introduction A number of questions

More information

Update on ARV based PrEP

Update on ARV based PrEP Update on ARV based PrEP Z Mike Chirenje MD FRCOG University of Zimbabwe, College of Health Sciences, Dept. of Obstetrics and Gynaecology Avondale, Harare, Zimbabwe chirenje@uz-ucsf.co.zw Controlling HIV

More information

Combination HIV Prevention

Combination HIV Prevention Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active

More information

Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection

Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection Pre-Exposure Prophylaxis: The New Frontier of Prophylaxis Against HIV Infection William F. Ryan Community Health Network PrEP Network Coordinator: Trevor Hedberg, MPH, CPH Supervising Health Educator:

More information

Drug development in relation to PrEP and the PROUD study

Drug development in relation to PrEP and the PROUD study Drug development in relation to PrEP and the PROUD study David Dolling Medical Statistician MRC Clinical Trials Unit 18 th October 2012 What is PrEP? - Pre-exposure Prophylaxis A strategy that uses antiretrovirals

More information

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants.

About FEM-PrEP. FEM-PrEP is also studying various behaviors, clinical measures, and health outcomes among the trial s participants. Fact Sheet About FEM-PrEP What is the FEM-PrEP clinical trial? FEM-PrEP is a Phase III randomized, placebo-controlled, clinical trial designed to assess the safety and effectiveness of a daily oral dose

More information

Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017

Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa. Jessica Haberer, MD, MS November 9, 2017 Adolescent PrEP Delivery: Strategies and Tools to Maximize Adherence Young Women in Africa Jessica Haberer, MD, MS November 9, 2017 Disclosures I have no conflicts to declare Grant funding: NIH, Gates

More information

OPTIONS. HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring. Elizabeth Gardiner, AVAC September 25, 2018

OPTIONS. HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring. Elizabeth Gardiner, AVAC September 25, 2018 OPTIONS Optimizing Prevention Technology Introduction On Schedule HOPE Protocol Team Meeting Lessons Learned from PrEP Rollout for the Dapivirine Ring Elizabeth Gardiner, AVAC September 25, 2018 Outline

More information

Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive:

Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive: Rationale for the call to action, progress to date and dealing with realities Rene Ekpini, MD, MPH Senior Adviser,

More information

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location

Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations. Age range. Study name and location Supplementary Material Table 5. Ongoing PrEP studies among young key population, young people, and key populations Study name and location ADAPT (HPTN 067) South Africa, Thailand, US (Harlem) Bangkok Tenofovir

More information

8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward

8/25/2016. Making Preexposure Prophylaxis Available in the Clinic: Considerations and Pathways Forward WORKSHOP SESSION: MAKING PREEXPOSURE PROPHYLAXIS AVAILABLE IN THE CLINIC: CONSIDERATIONS AND PATHWAYS FORWARD PRE-REGISTRATION IS REQUIRED PLEASE SEE THE CPT INFORMATION DESK IF THIS IS NOT YOUR SELECTED

More information

Antiretrovirals for HIV prevention:

Antiretrovirals for HIV prevention: Antiretrovirals for HIV prevention: Topical PrEP, Systemic PrEP and Treatment for Prevention Presentation at 6th International workshop on HIV treatment, pathogenesis and prevention research in resource-limited

More information

HIV / AIDS. Prevention In Our Lives

HIV / AIDS. Prevention In Our Lives HIV / AIDS Prevention In Our Lives Prevention In Our Lives: Produced by the Treatment Action Campaign. Authors: Published: September 2010 Conte n t s Introduction: Statistics on HIV in South Africa 2 Why

More information

The Evidence Base for Women

The Evidence Base for Women The Evidence Base for Women Dr. Busisiwe Msimanga-Radebe WHO South Africa country office ICASA 2017 Abidjan, Cote d Ivoire Combination prevention to break the cycle of HIV transmission Men

More information

International Partnership for Microbicides

International Partnership for Microbicides International Partnership for Microbicides New Directions in Microbicide Research Accelerating an HIV Prevention Revolution: A Roadmap Zeda F. Rosenberg, ScD, Chief Executive Officer Washington, DC, March

More information

Lessons from MSM PrEP pilots / demonstration projects. Kevin Rebe

Lessons from MSM PrEP pilots / demonstration projects. Kevin Rebe Lessons from MSM PrEP pilots / demonstration projects Kevin Rebe rebe@anovahealth.co.za PrEP Demonstration Projects US: Multisite demonstration project in San Francisco, Miami and Washington DC. South

More information

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program

PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the

More information

Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa

Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa Transmission Networks & Risk of HIV Infection in Young Women in KwaZulu-Natal, South Africa FIDSSA, Cape Town, November 2017 Quarraisha Abdool Karim, PhD Associate Scientific Director: CAPRISA Professor

More information

INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION

INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION INTRODUCTION TIMELINE: PrEP IMPLEMENTATION SA POLICY & GUIDELINES WHO guidelines [EXECUTIVE SUMMARY] NDoH PrEP policy [FULL] NDoH PrEP guidelines [FULL] FACILITY AUDIT TOOL IEC MATERIALS MONITORING & EVALUATION

More information

PROVIDERS VIEWS ON PREP FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA

PROVIDERS VIEWS ON PREP FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA results brief 2 PROVIDERS VIEWS ON PREP FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN TANZANIA FINDINGS FROM IMPLEMENTATION SCIENCE RESEARCH JUNE 2017 girls and young women (AGYW) continue to have high rates

More information

PrEP: Pre Exposure Prophylaxis

PrEP: Pre Exposure Prophylaxis PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose

More information

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017

HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland. An update for registered practitioners September 2017 HIV Pre-Exposure Prophylaxis (HIV PrEP) in Scotland An update for registered practitioners September 2017 Key Messages HIV is a major public health challenge for Scotland with an annual average of 359

More information

Prevention targets & scorecard

Prevention targets & scorecard Prevention targets & scorecard Context Three opportunities For the first time: Global programmatic targets (UN Political Declaration 2016) Translate into pragmatic country road map targets Country and

More information

PEP and PrEP: AWAAC 2014

PEP and PrEP: AWAAC 2014 Acknowledgements: HIVCS PEP guidelines group, Helen Rees, Slim Abdool Karim, Quarraisha Abdool Karim, Clinical Care Options, Edwina Wright, Jared Baeton, AETC PEP and PrEP: AWAAC 2014 Francois Venter Wits

More information

Renewing Momentum in the fight against HIV/AIDS

Renewing Momentum in the fight against HIV/AIDS 2011 marks 30 years since the first cases of AIDS were documented and the world has made incredible progress in its efforts to understand, prevent and treat this pandemic. Progress has been particularly

More information

Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 3: ROLLOUT SCENARIOS

Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 3: ROLLOUT SCENARIOS 3 Plan 4 PrEP: Toolkit for Oral PrEP Implementation STEP 3: ROLLOUT SCENARIOS About this toolkit WHAT IS THE PURPOSE AND CONTENTS OF THIS TOOLKIT? This toolkit was developed and used by the OPTIONS Consortium

More information

Promoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia

Promoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia Promoting FP/RH-HIV/AIDS Integration: A Summary of Global Health Initiative Strategies in Ethiopia, Kenya, Tanzania, and Zambia The Global Health Initiative (GHI) is an integrated approach to global health

More information

Strategic use of antiretroviral drugs to prevent HIV transmission

Strategic use of antiretroviral drugs to prevent HIV transmission Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases

More information

DREAMS PROJECT. Zandile Mthembu. Programme Manager AWACC October 2016

DREAMS PROJECT. Zandile Mthembu. Programme Manager AWACC October 2016 DREAMS PROJECT Zandile Mthembu Programme Manager AWACC 2016 06 October 2016 Presentation outline Background and Objectives Implementation Approach Interventions/Tools Progress Conclusion QUIZ QUESTION

More information

Understanding the Impact of an HIV Intervention Package for Adolescents

Understanding the Impact of an HIV Intervention Package for Adolescents Understanding the Impact of an HIV Intervention Package for Adolescents Faikah Bruce Supervisors: Dr. Leigh Johnson (UCT - CIDER) and Prof. Alex Welte (SU - SACEMA) 1 Contents Introduction Literature Review

More information

SUMMARY MEETING REPORT. Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service. Geneva, 7 8 May 2013

SUMMARY MEETING REPORT. Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service. Geneva, 7 8 May 2013 SUMMARY MEETING REPORT Annual stakeholders and partners meeting AIDS Medicines and Diagnostics Service Geneva, 7 8 May 2013 Department of HIV/AIDS HIV Technologies and Commodities May 2013 WHO/HIV/2013.6

More information

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination

Using PrEP as Harm Reduction. Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Be PrEPared! Using PrEP as Harm Reduction Iman Little, MPH Team Lead, Preventative Services Chicago Center for HIV Elimination Ricky Hill, MA, PhD candidate Team Lead, Community Partnerships and Engagement

More information

DREAMS. Heather Watts M.D. Senior Technical Advisor Office of the US Global AIDS Coordinator US Department of State

DREAMS. Heather Watts M.D. Senior Technical Advisor Office of the US Global AIDS Coordinator US Department of State DREAMS Heather Watts M.D. Senior Technical Advisor Office of the US Global AIDS Coordinator US Department of State Key Populations Vary by Location Young women are the major key population in Sub-Saharan

More information

Investing for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS

Investing for Impact Prioritizing HIV Programs for GF Concept Notes. Lisa Nelson, WHO Iris Semini, UNAIDS Investing for Impact Prioritizing HIV Programs for GF Concept Notes Lisa Nelson, WHO Iris Semini, UNAIDS Top 5 Lessons Learned 1 2 3 4 5 Prioritize within the allocation amount Separate above allocation

More information

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital

PEP and PREP. Dr David Hawkins Chelsea and Westminster Hospital PEP and PREP Dr David Hawkins Chelsea and Westminster Hospital Opportunities for biomedical interventions YEARS HOURS 72 HOURS YEARS Prior to exposure Exposure (pre-coital/ coital) Exposure (pre-coital/

More information

Summary of PEPFAR State of Program Area (SOPA): Care & Support

Summary of PEPFAR State of Program Area (SOPA): Care & Support Summary of PEPFAR State of Program Area (SOPA): Care & Support Prepared by E. Michael Reyes, MD, MPH (Original SOPA is a 45 page document) Introduction: Care and Support refers to the broad array of non-art

More information

Overview November 2017

Overview November 2017 Pre-Exposure Prophylaxis Implementation in South Africa Overview November 2017 PrEP & T&T Implementation Process 2015 2017 Consultation Policy Implementation October 2015 (Pre- policy) 1 st Draft December

More information

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012

MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled

More information

LOGFRAME TEMPLATE FOR SWAZILAND. SIDA s Contributions

LOGFRAME TEMPLATE FOR SWAZILAND. SIDA s Contributions 1 Outcome 7 countries have addressed barriers to efficient and effective linkages between HIV and SRHR policies and services as part of strengthening health systems to increase access to and use of a broad

More information

Overview of ARV-based prevention trials

Overview of ARV-based prevention trials Overview of ARV-based prevention trials Catherine Hankins BA MD MSc CCFP FRCPC Deputy Director, Science Amsterdam Institute for Global Health and Development; Department of Global Health, Academic Medical

More information

Review of planned trials and key emerging issues for Thailand

Review of planned trials and key emerging issues for Thailand Review of planned trials and key emerging issues for Thailand Frits van Griensven, PhD, MPH Silom Community Clinic Thailand MOPH US CDC Collaboration US Centers for Disease Control and Prevention ilom

More information

OPTIONS Country Situation Analysis Interim Findings: Kenya

OPTIONS Country Situation Analysis Interim Findings: Kenya FEBRUARY 2017 OPTIONS Country Situation Analysis Interim Findings: Kenya FSG in partnership with LVCT Health OPTIONS Introduction KENYA One of five cooperative agreements awarded by USAID with PEPFAR funding

More information

Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials:

Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Pre-Exposure Topical Microbicides and Oral Prophylaxis Trials: Rationale, Designs & Issues Connie Celum, MD, MPH Patrick Ndase, MBChB, MPH May 2007 Regional MTN Meeting Importance of HIV prevention Antiretroviral

More information

Combination prevention: Public health and human rights imperatives

Combination prevention: Public health and human rights imperatives Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination

More information

Projected Demand for HIV Diagnostic Tests

Projected Demand for HIV Diagnostic Tests Projected Demand for HIV Diagnostic Tests John Stover, Yu Teng, Adebiyi Adesina, Eline Korenromp On behalf of the Diagnostics Forecasting Technical Working Group (CDC, CHAI, GFATM, PfSCM, UNAIDS, UNICEF,

More information

Biomedical Prevention in HIV

Biomedical Prevention in HIV Biomedical Prevention in HIV CHART - CCAS-CDC 3 RD Joint Meeting Montego Bay, Jamaica August 21-26,2011 Presented by Tina Hylton-Kong, ERTU-CHART Some Slides from Impact of ART on HIV Transmission Wafaa

More information

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013

Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Biomedical HIV Prevention & PrEP Pre exposure Prophylaxis 2013 Community Education Team The AIDS Institute/AIDS Alliance Be the Generation to End the AIDS Epidemic bethegeneration.nih.gov www.aids-alliance.org/education/vaccine

More information

Update on Antiretroviral-Based HIV Prevention

Update on Antiretroviral-Based HIV Prevention Update on Antiretroviral-Based HIV Prevention Prof. Janneke van de Wijgert University of Liverpool, Institute of Infection and Global Health Click to edit Master subtitle style 12th European Meeting on

More information

Elements of Reproductive Health

Elements of Reproductive Health SEXUAL& REPRODUCTIVE HEALTH and HIV/AIDS INTEGRATION: Issues for consideration Dr. Chris Baryomunsi, MP Parliament of Uganda Elements of Reproductive Health Safe motherhood Family Planning Prevention and

More information

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day

Getting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow

More information

Nairobi City s Progress Towards Ending the HIV Epidemic. Dr. Carol Ngunu-Gituathi Deputy Director, Health Services, NAIROBI

Nairobi City s Progress Towards Ending the HIV Epidemic. Dr. Carol Ngunu-Gituathi Deputy Director, Health Services, NAIROBI Nairobi City s Progress Towards Ending the HIV Epidemic Dr. Carol Ngunu-Gituathi Deputy Director, Health Services, NAIROBI Presentation Outline Kenya HIV Situation City County Profile Key Achievements

More information

Uganda Actions for Acceleration FP2020

Uganda Actions for Acceleration FP2020 Uganda Actions for Acceleration FP2020 Other modern 2.7% Country Snapshot Country Snapshot Modern Contraceptive Method Mix Condoms (m) 13.7% Pills 8.2% Injection 51.8% Sterilization (f) 5.9% IUD 1.2% Sterilization

More information

Steady Ready Go! teady Ready Go. Every day, young people aged years become infected with. Preventing HIV/AIDS in young people

Steady Ready Go! teady Ready Go. Every day, young people aged years become infected with. Preventing HIV/AIDS in young people teady Ready Go y Ready Preventing HIV/AIDS in young people Go Steady Ready Go! Evidence from developing countries on what works A summary of the WHO Technical Report Series No 938 Every day, 5 000 young

More information

Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018

Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018 Which Scale Up Strategies/Programmatic Mixes are most Cost-Effective? Iris Semini UNAIDS May 2018 Outline Scaling up for Impact Critical Point of the Response Choices of strategies Accelerating Implementation

More information

FHI Study 10015: FEM-PrEP

FHI Study 10015: FEM-PrEP FHI Study 10015: FEM-PrEP Phase 3, multi-center, double-blind, randomized, placebo-controlled effectiveness and safety study to assess the role of Truvada in preventing HIV acquisition in women MTN Annual

More information

USG Update on Family Planning/HIV Integration

USG Update on Family Planning/HIV Integration USG Update on Family Planning/HIV Integration Nithya Mani, USAID/Office of HIV/AIDS Jennifer Mason, USAID/Office of Population and Reproductive Health IAWG SRH and HIV Linkages Meeting March 9-10, 2015

More information

Differentiated Service Delivery: Taking Innovative Delivery Models to Scale

Differentiated Service Delivery: Taking Innovative Delivery Models to Scale Differentiated Service Delivery: Taking Innovative Delivery Models to Scale Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University Outline The Promise of Differentiated Service Delivery (DSD) Scale-up

More information